Its success, along with Moderna's vaccine, showcased the ability of biotechnology to respond swiftly to global health crises.
Pfizer's COVID-19 vaccine, developed in partnership with BioNTech, received emergency use authorization in record time. Its success, along with Moderna's vaccine, showcased the ability of biotechnology to respond swiftly to global health crises. Moreover, the adaptability of mRNA vaccines to emerging variants underscores the resilience of biotech in the face of evolving pathogens.